Risk factors of unexplained early neurological deterioration after treatment for ischemic stroke due to large vessel occlusion: a post hoc analysis of the HERMES study.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 08 09 2021
accepted: 25 01 2022
pubmed: 17 2 2022
medline: 17 2 2023
entrez: 16 2 2022
Statut: ppublish

Résumé

Early neurological deterioration (END) after endovascular treatment (EVT) in patients with anterior circulation acute ischemic stroke (AIS) is associated with poor outcome. END may remain unexplained by parenchymal hemorrhage (UnEND). We aim to analyze the risk factors of UnEND in the medical management (MM) and EVT arms of the HERMES study. We conducted a post-hoc analysis of anterior AIS patients who underwent EVT for proximal anterior occlusions. Risk factors of UnEND, defined as a worsening of ≥4 points between baseline National Institutes of Health Stroke Scale (NIHSS) and NIHSS at 24 hours without hemorrhage, were compared between both arms using mixed logistic regression models adjusted for baseline characteristics. An interaction analysis between the EVT and MM arms for risk factors of UnEND was conducted. Among 1723 patients assessable for UnEND, 160 patients experienced an UnEND (9.3%), including 9.1% (78/854) in the EVT arm and 9.4% (82/869) in the MM arm. There was no significant difference in the incidence of UnEND between the two study arms. In the EVT population, independent risk factors of UnEND were lower baseline NIHSS, higher baseline glucose, and lower collateral grade. In the MM population, the only independent predictor of UnEND was higher baseline glucose. However, we did not demonstrate an interaction between EVT and MM for baseline factors as risk factors of UnEND. UnEND was, similarly in both treatment groups, a significant predictor of unfavorable outcome in both the EVT (p<0.001) and MM (p<0.001) arms. UnEND is not an uncommon event, with a similar rate which ever treatment arm is considered. In the clinical scenario of AIS due to large vessel occlusion, no patient-related factor seems to increase the risk for UnEND when treated by EVT compared with MM.

Sections du résumé

BACKGROUND BACKGROUND
Early neurological deterioration (END) after endovascular treatment (EVT) in patients with anterior circulation acute ischemic stroke (AIS) is associated with poor outcome. END may remain unexplained by parenchymal hemorrhage (UnEND). We aim to analyze the risk factors of UnEND in the medical management (MM) and EVT arms of the HERMES study.
METHODS METHODS
We conducted a post-hoc analysis of anterior AIS patients who underwent EVT for proximal anterior occlusions. Risk factors of UnEND, defined as a worsening of ≥4 points between baseline National Institutes of Health Stroke Scale (NIHSS) and NIHSS at 24 hours without hemorrhage, were compared between both arms using mixed logistic regression models adjusted for baseline characteristics. An interaction analysis between the EVT and MM arms for risk factors of UnEND was conducted.
RESULTS RESULTS
Among 1723 patients assessable for UnEND, 160 patients experienced an UnEND (9.3%), including 9.1% (78/854) in the EVT arm and 9.4% (82/869) in the MM arm. There was no significant difference in the incidence of UnEND between the two study arms. In the EVT population, independent risk factors of UnEND were lower baseline NIHSS, higher baseline glucose, and lower collateral grade. In the MM population, the only independent predictor of UnEND was higher baseline glucose. However, we did not demonstrate an interaction between EVT and MM for baseline factors as risk factors of UnEND. UnEND was, similarly in both treatment groups, a significant predictor of unfavorable outcome in both the EVT (p<0.001) and MM (p<0.001) arms.
CONCLUSIONS CONCLUSIONS
UnEND is not an uncommon event, with a similar rate which ever treatment arm is considered. In the clinical scenario of AIS due to large vessel occlusion, no patient-related factor seems to increase the risk for UnEND when treated by EVT compared with MM.

Identifiants

pubmed: 35169030
pii: neurintsurg-2021-018214
doi: 10.1136/neurintsurg-2021-018214
doi:

Substances chimiques

Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

221-226

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: PW is member of the editorial board of the Journal of Neurointerventional Surgery.

Auteurs

Romain Bourcier (R)

Neuroradiology, Université de Nantes, Nantes, Pays de la Loire, France romain.bourcier@chu-nantes.fr.

Mayank Goyal (M)

Diagnostic Imaging, University of Calgary, Calgary, Alberta, Canada.

Keith W Muir (KW)

Centre for Stroke & Brain Imaging University of Glasgow, University of Glasgow, Glasgow, UK.

Hubert Desal (H)

Neuroradiology, University Hospital of Nantes, Nantes, France.

Diederik W J Dippel (DWJ)

Neurology, Erasmus Mc University Medical Center, Rotterdam, The Netherlands.

Charles B L M Majoie (CBLM)

Radiology and Nuclear Medicine, Amsterdam UMC - Locatie AMC, Amsterdam, North Holland, The Netherlands.

Wim H van Zwam (WH)

Radiology, Maastricht University Medical Center, Maastricht, The Netherlands.

Tudor G Jovin (TG)

Neurology, Cooper University Hospital, Camden, New Jersey, USA.

Peter J Mitchell (PJ)

Radiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Andrew M Demchuk (AM)

Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Departments of Clinical Neuroscience and Radiology, Hotchkiss Brain Institute, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Robert J van Oostenbrugge (RJ)

Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Scott B Brown (SB)

Altair Biostatistics, Mooresville, New York, USA.

Bruce Campbell (B)

Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, Melbourne, Austria.

Philip White (P)

Institute for Ageing & Health, Newcastle University, Newcastle upon Tyne, UK.
Neuroradiology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.

Michael D Hill (MD)

Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Clinical Neurosciences, Foothills Medical Centre, Calgary, Alberta, Canada.

Jeffrey L Saver (JL)

Neurology, UCLA, Los Angeles, California, USA.
Comprehensive Stroke Center and Neurology, David Geffen School of Medicine, Los Angeles, California, USA.

Christian Weimar (C)

Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Duisburg, Nordrhein-Westfalen, Germany.

Reza Jahan (R)

Interventional Neuroradiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA.

Francis Guillemin (F)

CIC 1433 Epidémiologie clinique, University of Lorraine and University Hospital of Nancy, Nancy, France.

Serge Bracard (S)

Neuroradiology, University of Lorraine and University Hospital of Nancy, Nancy, France.

Olivier Naggara (O)

Department of Neuroradiology, Saint Anne Hospital Centre, Paris, Île-de-France, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH